Earnings summaries and quarterly performance for HOOKIPA Pharma.
Research analysts who have asked questions during HOOKIPA Pharma earnings calls.
Alec Stranahan
Bank of America
3 questions for HOOK
Also covers: AGIO, ALEC, BTAI +11 more
RB
Roy Buchanan
Citizens JMP
3 questions for HOOK
Also covers: ABUS, CDTX, CVAC +5 more
Andrew Berens
Leerink Partners
2 questions for HOOK
Also covers: AGIO, ARVN, BGNE +6 more
Asthika Goonewardene
Truist Securities
2 questions for HOOK
Also covers: ALLO, AUTL, BNTX +9 more
Suzanne van Voorthuizen
Kempen & Co
2 questions for HOOK
Also covers: ARGX, BNTX, GMAB +3 more
AH
Arthur He
H.C. Wainwright & Co.
1 question for HOOK
Also covers: ADAP, AUPH, ITOS +1 more
Brian Abrahams
RBC Capital Markets
1 question for HOOK
Also covers: ACAD, ATAI, BCRX +17 more
CL
Christopher Lu
SVB Leerink
1 question for HOOK
Also covers: EXEL
DC
Debjit Chattopadhyay
Guggenheim Securities
1 question for HOOK
Also covers: BEAM, BOLD, IONS +5 more
IG
Ingrid Gafanhão
Kempen
1 question for HOOK
R
RK
HC Wainright
1 question for HOOK
Also covers: CLGN, MDWD
Recent press releases and 8-K filings for HOOK.
HOOKIPA Pharma Sells Oncology Assets to NeoTrail Therapeutics
HOOK
M&A
- HOOKIPA Pharma Inc. announced the sale of its immuno-oncology related assets to NeoTrail Therapeutics, Inc.
- The sold assets primarily consist of the HB-200 (eseba-vec) and HB-700 development programs.
- The asset purchase agreement was signed on January 28, 2026, with the transaction expected to close in the second quarter of 2026.
- The purchase price for the assets remains undisclosed.
4 days ago
Quarterly earnings call transcripts for HOOKIPA Pharma.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more